Skip Navigation
Skip to contents

JYMS : Journal of Yeungnam Medical Science

Indexed in: ESCI, Scopus, PubMed,
PubMed Central, CAS, DOAJ, KCI
FREE article processing charge
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
1 "Immunotherapy"
Filter
Filter
Article category
Keywords
Publication year
Authors
Review article
An update on immunotherapy with PD-1 and PD-L1 blockade
Sung Ae Koh
Yeungnam Univ J Med. 2021;38(4):308-317.   Published online September 9, 2021
DOI: https://doi.org/10.12701/yujm.2021.01312
  • 4,462 View
  • 95 Download
  • 2 Crossref
AbstractAbstract PDF
Cancer is the leading cause of death and is on the rise worldwide. Until 2010, the development of targeted treatment was mainly focused on the growth mechanisms of cancer. Since then, drugs with mechanisms related to tumor immunity, especially immune checkpoint inhibitors, have proven effective, and most pharmaceutical companies are striving to develop related drugs. Programmed cell death-1 and programmed cell death ligand-1 inhibitors have shown great success in various cancer types. They showed durable and sustainable responses and were approved by the U.S. Food and Drug Administration. However, the response to inhibitors showed low percentages of cancer patients; 15% to 20%. Therefore, combination strategies with immunotherapy and conventional treatments were used to overcome the low response rate. Studies on combination therapy have typically reported improvements in the response rate and efficacy in several cancers, including non-small cell lung cancer, small cell lung cancer, breast cancer, and urogenital cancers. The combination of chemotherapy or targeted agents with immunotherapy is one of the leading pathways for cancer treatment.

Citations

Citations to this article as recorded by  
  • Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
    Wonyoung Jo, Taejoon Won, Abdel Daoud, Daniela Čiháková
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Therapeutic targeting of thioredoxin reductase 1 causes ferroptosis while potentiating anti-PD-1 efficacy in head and neck cancer
    Ming-Shou Hsieh, Hang Huong Ling, Syahru Agung Setiawan, Mardiah Suci Hardianti, Iat-Hang Fong, Chi-Tai Yeh, Jia-Hong Chen
    Chemico-Biological Interactions.2024; 395: 111004.     CrossRef

JYMS : Journal of Yeungnam Medical Science